Nutrition.ad Nutrition.ad
Nutrition News

New research spotlights functional foods and supplements for lowering LDL cholesterol

A new review and several clinical analyses add evidence for plant sterols, soluble fiber and select nutraceuticals, while experts emphasize safety, labeling and ongoing outcomes trials.

New research spotlights functional foods and supplements for lowering LDL cholesterol
#LDL cholesterol#plant sterols#soluble fiber#nutraceuticals#functional foods#cardiovascular risk#lipid guidelines#meta analysis

New research spotlights functional foods and supplements for lowering LDL cholesterol

Functional foods and supplements draw renewed attention for cholesterol lowering, as outcomes evidence remains limited

Functional foods, fortified ingredients and dietary supplements are drawing renewed scientific and public-health attention as adjuncts for lowering low-density lipoprotein cholesterol (LDL-C), with recent peer-reviewed reviews and meta-analyses highlighting modest but measurable LDL reductions from certain ingredients—especially plant sterols/stanols and soluble fiber—alongside continued caution from major medical organizations about variable quality, safety considerations and limited evidence on hard cardiovascular outcomes.

A broad review in PMC describing mechanisms and efficacy across functional ingredients reported that multiple food-derived compounds can lower cholesterol through pathways including reduced intestinal absorption, increased bile acid excretion and altered hepatic cholesterol synthesis, and proposed a “cholesterol-lowering capacity index” to compare candidates across products and formulations. The paper described plant sterols, soluble fibers and red yeast rice among the best-known options, while emphasizing differences in evidence strength across ingredients and formulations.

Separately, a meta-analysis of randomized controlled trials in Food & Nutrition Research found that plant sterol–containing products reduced LDL cholesterol by 0.31 mmol/L compared with placebo, though trial-to-trial heterogeneity was significant—an indication results varied across studies and products.

New and ongoing studies examine nutraceutical blends and next-generation therapies

Beyond single ingredients, investigators have continued testing multi-ingredient nutraceutical blends. A six-month Italian study reported by NutraIngredients found a five-ingredient supplement blend—containing berberine, olive, fenugreek, artichoke and sunflower seed extract—was associated with LDL-C reductions in adults with borderline dyslipidemia. The report characterized participants as having “borderline” lipid abnormalities and framed the findings as relevant to early risk management, though details on long-term cardiovascular outcomes were not the focus of the coverage.

At the pharmaceutical frontier, UT Southwestern reported results from an experimental pill that “dramatically” reduced LDL cholesterol in a clinical trial setting, while noting a separate trial is underway to determine whether LDL reductions translate into fewer heart attacks and strokes—an outcomes question that remains central across both drug and non-drug lipid-lowering strategies.

Expert and institutional guidance stresses evidence quality and safety

Clinical organizations and federal health agencies have consistently underscored that supplements are not interchangeable with prescription therapy, and that evidence and safety vary widely by product.

  • The Mayo Clinic overview on cholesterol-lowering supplements notes some products may help lower cholesterol, but emphasizes variability in clinical effectiveness and potential risks, including interactions and inconsistent supplement content across brands.
  • The National Center for Complementary and Integrative Health (NCCIH) summarizes evidence for “natural products,” reporting that some soy foods may have small cholesterol-lowering effects while results for supplements can be less consistent, and highlighting the importance of safety considerations and product variability.
  • The American Heart Association frames cholesterol management as risk-factor prevention and treatment, situating diet and medications within broader cardiovascular prevention strategies rather than as interchangeable options.

In the U.S., federal labeling rules also shape how certain functional ingredients are marketed. The FDA’s regulation governing health claims for plant sterol/stanol esters and coronary heart disease risk describes high LDL cholesterol as a major modifiable risk factor and sets conditions under which claims may be made—an approach intended to tie marketing language to defined evidence and intake parameters.

Why plant sterols and soluble fiber remain leading “food-first” ingredients

Plant sterols/stanols and soluble fiber have remained central in clinical discussions because they act through well-characterized mechanisms and can be integrated into foods.

Plant sterols/stanols can reduce intestinal cholesterol absorption, while soluble fiber can bind bile acids and promote excretion, leading the liver to use more circulating cholesterol to produce bile acids. Cleveland Clinic’s overview of cholesterol nutrition highlights soluble fiber as a key dietary component associated with LDL reduction through bile-related mechanisms, and the Academy of Nutrition and Dietetics describes plant sterols/stanols as naturally present in foods and linked to lower total and LDL cholesterol in some contexts.

Still, research and guideline discussions continue to distinguish between lowering a lab value and proving reductions in heart attacks and strokes—an evidence gap that multiple experts and institutions note remains crucial for evaluating any lipid-lowering approach.

Industry and research pipeline broaden the “functional ingredient” landscape

A separate PMC review on AI-enabled functional ingredient development discussed the expanding pipeline of ingredients—including probiotics investigated for potential cholesterol-related effects—illustrating how the field is moving from traditional fortified foods toward bioactive compounds supported by emerging computational and translational research. A related MDPI Foods review similarly describes functional foods as a rapidly developing research area across chronic disease prevention, with cardiovascular risk reduction among key targets—though it also reflects that product development often outpaces definitive outcomes evidence.

References & Links

Back to News